QuickChek Help your patients better understand their blood glucose results with the QuickChek™ booklet, a TRUEInsight Guide™, which teaches them the importance of blood glucose monitoring. This simple, easy-to-use tool allows patients to monitor their blood glucose, track results, identify trends and use this information to better manage and achieve …

Tekamlo™, a Combination of Aliskiren and Amlodipine Novartis Receives FDA Approval of Tekamlo™, a Combination of Aliskiren and Amlodipine to Treat High Blood Pressure: Tekamlo is approved as initial therapy for patients who are likely to need multiple drugs to achieve their blood pressure goals and as replacement therapy for …

Medicare to Cover Smoking Cessation: Good news for seniors who want to quit smoking: Medicare will now cover tobacco cessation counseling. Previously, Medicare only covered smoking cessation counseling if a recipient had already been diagnosed with a tobacco-related disease or showed symptoms of such a disease. All Medicare beneficiaries already …

Diabetes Incidence May Depend on Socioeconomic Status: It seems that women who make less money than their counterparts are more likely to develop Type 2 diabetes, Canadian researchers found in a new study. The study, which was conducted over a 14-year period from 1994 to 2008 by Statistics Canada, found …

Simple Solution to Preventing Risk for Diabetes: A change in diet may help reverse the growth in the number of people with Type 2 diabetes. While this number has grown significantly over the past twenty years, British researchers say one specific change may help. They reviewed several studies and discovered …

A review of two intensive therapies to lower blood glucose levels in newly diagnosed Type 2 patients…

Certain urine proteomic profiles may be useful biomarkers in the differential diagnosis of diabetic glomerulosclerosis, researchers report in Diabetes Care… 

Intensive dietary advice has the potential to appreciably improve glycemic control and anthropometric measures in patients with Type 2 diabetes who are hyperglycemic despite optimized drug treatment… 

Given the prevalence of lipid abnormalities in patients with diabetes, dual PPAR-α/γ agonists (glitazars) could potentially benefit patients with diabetes. A phase II trial examining a novel dual PPAR agonist, aleglitazar, showed that therapy with this agent reduced hyperglycemia and favorably modified levels of HDL-C and triglycerides with an acceptable …

A third of patients on lipid-lowering therapy received inadequate doses of generic simvastatin after being switched from atorvastatin (Lipitor), an analysis of a large pharmacy database showed…